American Genesis: Ibogaine

An African plant roots in the Homeland

The history of ibogaine in the United States is a fragmented tale of obscure experimental use followed by bursts of underground innovation. A brief period of federal interest eventually gave way to the current Schedule 1 designation. This story is littered with anecdotes of fervent advocates, personal betrayal, and legal battles over patents.

Ibogaine was first isolated from the African shrub, Tabernanthe iboga, in 1901 by French researchers. It was studied mainly in Europe as a stimulant and tonic rather than in the U.S. In the mid‑20th century, researchers and federal programs briefly explored ibogaine at the infamous federal “narcotics farm” in Lexington, Kentucky. In the 1950s, researchers, including Dr. Harris Isbell, administered ibogaine to inmates under CIA-funded programs. Primary data from Isbell’s experiments, including the 1955 study on prisoners, are unavailable despite confirmation that the research occurred. This absence of records contributed to ibogaine’s early obscurity in U.S. addiction research.

The pivotal U.S. turning point came in 1962, when a 19-year-old heroin user, Howard Lotsof, took ibogaine recreationally and observed that his opioid withdrawal and craving were unexpectedly absent afterward. He was to become the Johnny Appleseed of ibogaine as he introduced his discovery to other people with opioid and stimulant dependence and began collecting anecdotal reports. He found that a single high dose could markedly blunt withdrawal and craving for heroin, methadone, cocaine, alcohol, and nicotine. His work and advocacy related to ibogaine cannot be overestimated and a deep dive into his influence is warranted.

Lotsof became the first person in the West to systematically promote ibogaine as an addiction‑interruption treatment, despite having no doctoral degree or formal medical training. He obtained a series of U.S. patents on ibogaine for the “rapid interruption” of opioid, stimulant, alcohol, nicotine, and poly‑drug dependence. In the 1980s he founded NDA International, convinced a Belgian manufacturer to produce ibogaine capsules, and supported treatments and small open trials in the Netherlands. Lotsof provided pilot human and observational data that helped persuade the U.S. National Institute on Drug Abuse to open a formal ibogaine research program. This eventually led to FDA clearance of a Phase 1 trial in the early 1990s.

While ibogaine still moved like a rumor through the underground, Dr. Deborah Mash and Lotsof began a collaboration based on their shared interest in ibogaine. Lotsof was the evangelist, an apostle of a West African root bark he was certain could break the chains of withdrawal. Mash was the scientist with a lab and the ability to conduct clinical trials. Lotsof brought structure with his numerous patents and a company that he had already formed. He had already staked legal claim to ibogaine as a treatment for addiction, but he needed legitimacy and data from real human trials. In 1993, the FDA authorized Dr. Mash and colleagues at the University of Miami to conduct a Phase 1 safety and pharmacokinetic trial. This represented the high‑water mark for sanctioned ibogaine research in the U.S. By 1995 NIDA review committees decided not to continue funding and terminated the ibogaine project. Any new ibogaine grant applications were labeled “Not for Further Consideration,” effectively freezing federally backed human trials in the U.S.

For a time, Mash and Lotsof moved in parallel with his mythos and her methods. She dosed subjects, drew blood, tracked vitals, and followed the drug downstream into its metabolite, noribogaine. This compound was the quieter chemical shadow that lingered after the storm of the trip. In noribogaine Dr. Mash saw something new, a candidate molecule that might one day step out from ibogaine’s long, haunted silhouette and stand on its own.

The moment noribogaine appeared as more than a lab curiosity, it became a cause of disagreement. There were patents to be written and names to be frozen forever in intellectual property documents. Mash and her colleagues showed up as inventors on one noribogaine patent while Lotsof’s company held the rights. Then came another patent from Lotsof for “Noribogaine Plus.” This one, Mash would later claim, folded in insights derived from her research, but now the inventor list shifted. Lotsof, who did not pipette or chase peaks across chromatograms, appeared as the inventor. Mash and her team were not listed. This created a fissure in the advocacy camp. The shared story of a visionary discoverer and an academic partner gave way to the more familiar American narrative. Collaboration turned into litigation. Mash sued Lotsof and NDA, arguing that her work had been repurposed into patents that erased her role while preserving the revenue streams for others.

The relationship soured into a familiar archetype. The underground prophet and the university scientist, once briefly aligned against a skeptical world, were now locked in a dispute over the spoils of a medicine that still wasn’t legal. What began as a partnership in service of a radical addiction treatment ended as a reminder that even in the psychedelic frontier, the oldest forces of control, credit, and capital, wait patiently at the gate.

Lotsof co‑authored scientific papers in the Journal of Ethnopharmacology and the American Journal on Addictions, trying to build a bridge between underground practice and mainstream addiction science. His efforts helped seed both regulated and underground ibogaine treatment networks. Even though ibogaine remains illegal for clinical use in the U.S., thousands of people worldwide have sought ibogaine detox protocols that trace directly back to Lotsof’s discovery and advocacy. He died in 2010, but within psychedelic and harm‑reduction circles he is remembered as the person who recognized and championed ibogaine’s anti‑addictive potential long before researchers took it seriously.

Within the U.S., ibogaine remains illegal, but small underground circles continue to import the drug and administer it informally. Dosing and setting is often based on both Lotsof’s protocols and West African ceremonial traditions, with varying and sometimes unsafe clinical practices. Ibogaine has become part of a broader “psychedelic renaissance” conversation in the U.S., alongside psilocybin and MDMA, but remains in a more marginal and controversial position because of its potential cardiotoxicity and demanding treatment course.

In 2025, Texas allocated a large state grant program (reported as $50,000,000) to fund clinical research on ibogaine and related compounds for opioid and other substance use disorders. A few other states are moving to fund or authorize ibogaine clinical trials, but these bills do not legalize general use. They only allow ibogaine within FDA‑regulated research programs or future FDA‑approved indications.

Colorado’s psychedelic framework allows ibogaine to be considered for inclusion in its regulated “natural medicine” program. The primary issue is related to the sourcing of ibogaine that is in alliance with the Nagoya Protocol. How above ground treatment centers will emerge in Colorado is yet to be determined. The issue of potentially lethal cardiac side effects, though extremely rare, introduces the issue of liability for any above ground treatment centers. The actual length of an ibogaine experience all but guarantees it will not become offered in an outpatient manner like the psilocybin treatment centers in Oregon.

Numerous national and regional ibogaine advocacy organizations have risen in the US with a stated goal of influencing government policy and promoting research. Well financed nonprofit Veterans organizations have emerged in support of treatment related to PTSD. Things are moving quickly in the U.S. but not fast enough for those carrying an opioid burden. How long will it be until Lotsof’s mission of safe above ground ibogaine treatment in his home country is accomplished?

Colorado is poised to be the breakthrough state but the lack of scalability based on potential costs is an immense challenge to addressing the human need. For most suffering from opioid addiction, the option of accessible and affordable ibogaine treatment in the U.S. is a pipe dream. Until that dream is realized, treatment in the underground and the gray offshore zones are the only options.